PD-1 Inhibitor and Nab-paclitaxel and Bevacizumab in CUP
Status:
Not yet recruiting
Trial end date:
2023-05-03
Target enrollment:
Participant gender:
Summary
This trial is a single-center, prospective, single-arm Phase II clinical study. The purpose
is to evaluate the efficacy and safety of recombinant humanized anti-PD-1 monoclonal antibody
combined with albumin paclitaxel and bevacizumab in the second-line treatment of patients
with unknown primary tumors.